Research programme: central nervous system therapeutics - Inhibikase TherapeuticsAlternative Names: Dasatnib - Inhibikase Therapeutics; IkT-01427; IkT-01427/IkT-148009; IkT-148009; Nilotinib - Inhibikase Therapeutics
Latest Information Update: 27 Sep 2016
At a glance
- Originator Inhibikase Therapeutics
- Class Small molecules
- Mechanism of Action Protein tyrosine kinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Parkinson's disease; Progressive multifocal leukoencephalopathy